Skip to main content

Table 4 Univariable and multivariable analysis of OS according to various prognostic groups

From: Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer

Variable Univariable analysis Multivariable analysis
HR (95% CI) P-value HR (95% CI) P-value
Treatment Arm     
(A vs. B) 1.56 (0.60 to 4.16) 0.361   
Age (>50 vs. ≤50) 1.45 (0.56 to 3.75) 0.441   
IDC vs. ILC 1.34 (0.45 to 5.49) 0.462   
Grade (3 vs1/2) 1.79 (0.67 to 4.81) 0.244   
ER (+) vs. (−) 0.53 (0.21 to 1.35) 0.188   
PR (+) vs. (−) 0.31 (0.11 to 0.89) 0.030 0.31 (0.10 to 1.19) 0.071
HER2 (+) vs. (−) 1.22 (0.45 to 3.26) 0.692   
TN (yes) vs. (no) 1.75 (0.65 to 4.65) 0.267   
Ki67 (High) vs. (Low) 1.47 (0.50 to 4.16) 0.480   
pCR vs. non pCR 2.21 (0.88 to 6.64) 0.080 1.42 (0.08 to 2.32) 0.801
ALDH1 (+) vs. (−)     
 Baseline 1.10 (0.43 to 2.81) 0.831   
 Post NAC* 10.58 (1.65 to 14.68) 0.005 4.61 (1.30 to 23.00) 0.024
  1. ALDH1, aldehyde dehydrogenase-1; pCR, complete pathologic response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; TN, triple negative. *Post NAC, patients include ALDH1(−) as well as those with pCR.